Osteoporosis Drugs Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 16.12 Billion |
| Market Size (2029) | USD 20.32 Billion |
| CAGR (2024 - 2029) | 4.74 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Osteoporosis Drugs Market Analysis
The Osteoporosis Drugs Market size is estimated at USD 16.12 billion in 2024, and is expected to reach USD 20.32 billion by 2029, at a CAGR of 4.74% during the forecast period (2024-2029).
The rising prevalence of osteoporosis, along with the growing geriatric population and fragility fractures, is expected to drive demand for effective treatment solutions. These demographic and health trends are anticipated to significantly contribute to the expansion of the osteoporosis drugs market. For instance, according to a report published in the Archives of Osteoporosis Journal in April 2024, the prevalence of osteoporosis is rising, showing a prevalence of 15.9% in individuals aged 50 and over, with a significant gender disparity. Many osteoporosis-related fractures remain undiagnosed, and only 30% of diagnosed individuals receive proper treatment, especially with a pronounced treatment gap in men. This increasing need for diagnosis and treatment directly fuels demand for osteoporosis drugs, driving market growth.
Furthermore, spinal cord injuries are associated with the development of osteoporosis. For instance, according to a report published in the BMC Medicine Journal in July 2024, the rising incidence of spinal cord injuries, with an overall incidence rate of 23.77 per million people, leads to increased mobility challenges and a higher risk of bone-related complications. As individuals with spinal cord injuries are prone to developing osteoporosis due to prolonged immobility, the need for effective therapeutic interventions is becoming more urgent. This growing demand for osteoporosis management solutions is propelling the expansion of the osteoporosis drugs market.
Additionally, the rising launches and approvals by the market players are expected to boost the market growth during the forecast period. For instance, in November 2023, Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., received approval for a generic version of Forteo in the U.S. market. The teriparatide injection is indicated for the treatment of osteoporosis in select women and men. Similarly, in August 2022, the Ministry of Health, Labour, and Welfare (MHLW) approved the Edirol Tablet by Towa Pharmaceutical in Japan. Introducing new generic formulations and approvals of osteoporosis treatments enhances market accessibility and provides more therapeutic options, driving the growth of the osteoporosis drugs market by addressing unmet clinical needs.
In conclusion, the growth of the osteoporosis drugs market is driven by increasing incidences of osteoporosis, rising demand for effective treatments due to related fractures and injuries, and the introduction of new therapeutic formulations and approvals.
However, stringent approval and marketing regulations are expected to restrain the market growth.
Osteoporosis Drugs Market Trends
The RANKL Inhibitors Segment is Expected to Witness Significant Growth Over the Forecast Period
Receptor activators of nuclear factor kappa-Β ligand (RANKL) inhibitors are used to treat osteoporosis in patients at high risk of fracture. RANKL can also be combined with other drugs to convey a synergistic effect on the entire treatment system. The segment is expected to grow during the forecast period, driven by rising approvals of innovative RANKL inhibitors, which significantly contribute to its expansion.
The rising approvals of innovative RANKL inhibitors and their biosimilars contribute significantly to the segment's growth during the forecast period. For instance, in February 2023, the Food and Drug Administration (FDA) accepted Sandoz's Biologics License Application (BLA) for a proposed biosimilar to denosumab. Denosumab is an approved RANKL inhibitor for the treatment of postmenopausal women with osteoporosis.
Similarly, in May 2023, the European Medicines Agency accepted Sandoz’s marketing authorization applications for a biosimilar to denosumab to treat conditions such as osteoporosis and cancer-related bone complications. The applications cover a broad range of indications, including osteoporosis in postmenopausal women and men at higher risk of fractures. This regulatory progress is expected to drive growth in the RANKL inhibitors segment as biosimilar options increase accessibility to osteoporosis treatments.
Additionally, in April 2024, researchers at the University of Arkansas for Medical Sciences were awarded a USD 2.27 million NIH grant to investigate estrogen's role in preventing bone loss and osteoporosis by focusing on its impact on osteoclast activity. Their study aims to explore how estrogen inhibits RANKL-induced mitochondrial functions in osteoclasts, potentially offering new insights into osteoporosis treatment. This research could drive growth in the RANKL inhibitors market by uncovering mechanisms that reduce bone resorption and supporting the development of targeted therapies for osteoporosis.
In conclusion, the growth of the RANKL inhibitors segment is driven by rising regulatory approvals, advancements in biosimilar development, and research initiatives exploring innovative mechanisms to enhance osteoporosis treatment, improving accessibility and therapeutic efficacy.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is anticipated to hold a substantial share of the osteoporosis drugs market due to the rising incidence of osteoporosis, substantial investment in research and development, continuous product introductions and approvals, and the strong presence of market players in the region.
The high prevalence of osteoporosis is expected to boost the market's growth. For instance, according to a report published by the Government of Canada in July 2024, approximately 10% of the Canada population aged 40 and over are affected by osteoporosis, with women being four times more likely to report the condition than men. This higher risk for women is attributed to their lower initial bone density and faster bone mass loss with age.
Additionally, market players' launches and approvals of innovative drugs are expected to propel market growth during the forecast period. For instance, in November 2023, Apotex Corp. launched its teriparatide injection, a pre-filled pen designed for single-patient use to treat osteoporosis in the United States. The pen delivers 250 mcg/mL of Teriparatide, providing 28 daily doses of 20 mcg per pen.
Similarly, in December 2022, the FDA approved TYMLOS (abaloparatide), a parathyroid hormone-related peptide analog, to increase bone mineral density among men with osteoporosis at high risk for fracture. Radius Health, Inc. in the United States manufactures and markets the drug. Such growth strategies are expected to propel the growth of the regional market during the forecast period.
In conclusion, the high prevalence of osteoporosis, increasing product approvals and launches, and a strong concentration of market players in North America are expected to drive the growth of the osteoporosis drugs market significantly.
Osteoporosis Drugs Industry Overview
The osteoporosis drugs market is competitive and consists of several major players. Some of the companies currently dominating the market are Amgen Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc., and Pfizer Inc.
Osteoporosis Drugs Market Leaders
-
Amgen Inc.
-
Eli Lily and Company
-
F. Hoffmann La Roche
-
Merck & Co. Inc.
-
Pfizer Inc
*Disclaimer: Major Players sorted in no particular order
Osteoporosis Drugs Market News
- September 2024: The National Institute for Health and Care Excellence (NICE) in the UK approved abaloparatide, a potent anabolic therapy, for patients at elevated fracture risk, marking a significant advancement in osteoporosis treatment. Abaloparatide is gaining momentum in the global osteoporosis market due to its proven efficacy and increasing acceptance among healthcare professionals.
- March 2024: The FDA approved two interchangeable biosimilars: Jubbonti (denosumab-bbdz) injection for the U.S.-licensed Prolia (denosumab) and Wyost (denosumab-bbdz) injection for the U.S.-licensed Xgeva (denosumab), respectively. These products inhibit the RANKL/RANK interaction, preventing osteoclast-mediated bone degradation, and represent the one of the first interchangeable biosimilar for a RANKL inhibitor.
Osteoporosis Drugs Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Incidence of Osteoporosis
4.2.2 Rise in the Geriatric Population
4.3 Market Restraints
4.3.1 Stringent Approval and Marketing Regulations
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD)
5.1 By Drug Type
5.1.1 Parathyroid Hormone Therapy
5.1.2 Bisphosphonates
5.1.3 Calcitonin
5.1.4 RANKL Inhibitors
5.1.5 Other Drug Types
5.2 By Application
5.2.1 Primary Osteoporosis
5.2.2 Secondary Osteoporosis
5.3 Route of Administration
5.3.1 Oral
5.3.2 Injectable
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 Eli Lily and Company
6.1.3 F. Hoffmann La Roche
6.1.4 GlaxoSmithKline PLC
6.1.5 Merck & Co. Inc.
6.1.6 Novartis International AG
6.1.7 Pfizer Inc.
6.1.8 Radius Health Inc.
6.1.9 Strides Pharma Science Limited
6.1.10 Teva Pharmaceutical Industries Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Osteoporosis Drugs Industry Segmentation
As per the report's scope, osteoporosis drugs are pharmacological agents designed to prevent bone loss, enhance bone density, and reduce the risk of fractures in individuals with weakened skeletal structures due to reduced bone mass. These drugs typically work by either inhibiting bone resorption or stimulating bone formation, offering therapeutic solutions to manage and treat osteoporosis. The osteoporosis drugs market is segmented by drug type, application, and geography. The drug type is further divided into parathyroid hormone therapy, bisphosphonates, calcitonin, RANKL Inhibitors, and other drug types. The application segment is further segmented into primary osteoporosis and secondary osteoporosis. The geography segment is further divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market size and forecast in value (USD) for the above segments.
| By Drug Type | |
| Parathyroid Hormone Therapy | |
| Bisphosphonates | |
| Calcitonin | |
| RANKL Inhibitors | |
| Other Drug Types |
| By Application | |
| Primary Osteoporosis | |
| Secondary Osteoporosis |
| Route of Administration | |
| Oral | |
| Injectable | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Osteoporosis Drugs Market Research FAQs
How big is the Osteoporosis Drugs Market?
The Osteoporosis Drugs Market size is expected to reach USD 16.12 billion in 2024 and grow at a CAGR of 4.74% to reach USD 20.32 billion by 2029.
What is the current Osteoporosis Drugs Market size?
In 2024, the Osteoporosis Drugs Market size is expected to reach USD 16.12 billion.
Who are the key players in Osteoporosis Drugs Market?
Amgen Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc. and Pfizer Inc are the major companies operating in the Osteoporosis Drugs Market.
Which is the fastest growing region in Osteoporosis Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Osteoporosis Drugs Market?
In 2024, the North America accounts for the largest market share in Osteoporosis Drugs Market.
What years does this Osteoporosis Drugs Market cover, and what was the market size in 2023?
In 2023, the Osteoporosis Drugs Market size was estimated at USD 15.36 billion. The report covers the Osteoporosis Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Osteoporosis Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
What are the emerging trends in the Osteoporosis Drugs Market?
The emerging trends in the Osteoporosis Drugs Market are a) Development and potential application of biologic drugs that target bone formation and resorption processes b) Exploring alternative delivery methods for improved patient compliance and potentially faster-acting medications
Osteoporosis Treatment Industry Report
The global osteoporosis drugs market is on the rise, propelled by medical advancements and an increasing elderly population susceptible to osteoporosis. Innovation in drug development is robust, particularly with new treatments like unique-cell based approaches and prostacyclin analogs. Key segments such as bisphosphonates and SGC stimulators are gaining traction for their potential in treating cardiopulmonary conditions. Oral medications remain preferred due to ease of administration, with growing interest in anabolic agents for patients at high risk of fractures. North America leads the market, supported by strong healthcare policies and infrastructure that facilitate the swift adoption of new treatments. Technological advancements in bone density scanning and drug delivery are improving treatment outcomes, with a notable shift towards biologic therapies and fracture prevention. Additionally, the integration of AI in drug development is enhancing personalization and efficacy in treatments. For further insights and a comprehensive market forecast, a detailed analysis is available for free download from Mordor Intelligence™.
